Treatment of Intracranial Aneurysms with the FRED X Flow Diverter Stent: Mid-term Angiographic and Safety Results.

IF 2.4 3区医学 Q2 CLINICAL NEUROLOGY

Clinical Neuroradiology Pub Date : 2025-01-23 DOI:10.1007/s00062-024-01487-z

David W Wen, James Ayre, Mani Puthuran, Paul Maliakal, Souhyb Masri, Richard Pullicino, Aubrey Smith, Feyi Babatola, Gilbert Gravino, Nasr Abdelsalam, Hamed Nejadhamzeeigilani, Arun Chandran

{"title":"Treatment of Intracranial Aneurysms with the FRED X Flow Diverter Stent: Mid-term Angiographic and Safety Results.","authors":"David W Wen, James Ayre, Mani Puthuran, Paul Maliakal, Souhyb Masri, Richard Pullicino, Aubrey Smith, Feyi Babatola, Gilbert Gravino, Nasr Abdelsalam, Hamed Nejadhamzeeigilani, Arun Chandran","doi":"10.1007/s00062-024-01487-z","DOIUrl":null,"url":null,"abstract":"Purpose: The aim of our study was to assess the mid-term efficacy and safety of the FRED X flow diverting stent (FDS) in the treatment of intracranial aneurysms. The FRED X FDS is relatively new with limited data on its longer-term effectiveness and safety profile.Methods: Patients with intracranial aneurysms treated with the FRED X FDS at two UK centres, between March 2021 and July 2022 with at least 18 months follow-up, were retrospectively reviewed. Clinical, procedural and imaging data was analyzed.Results: Twenty-two patients with 24 aneurysms treated with the FRED X device, and had completed at least 18 months of follow-up, were included in this study. The rate of complete aneurysm occlusion (Raymond-Roy Class I) was 83.3% at a mean follow-up duration of 21.5 months. One case of major adverse event (4.3%) related to a post-procedural stroke which is also the only case of permanent neurological deficit (4.3%) in our cohort. Three cases of minor adverse events (13.0%) and 2 cases of asymptomatic adverse events (8.7%) were also recorded.Conclusion: Use of the FRED X FDS to treat intracranial aneurysms has acceptable safety profile and efficacy in the mid-term.","PeriodicalId":49298,"journal":{"name":"Clinical Neuroradiology","volume":" ","pages":""},"PeriodicalIF":2.4000,"publicationDate":"2025-01-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Neuroradiology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s00062-024-01487-z","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: The aim of our study was to assess the mid-term efficacy and safety of the FRED X flow diverting stent (FDS) in the treatment of intracranial aneurysms. The FRED X FDS is relatively new with limited data on its longer-term effectiveness and safety profile.

Methods: Patients with intracranial aneurysms treated with the FRED X FDS at two UK centres, between March 2021 and July 2022 with at least 18 months follow-up, were retrospectively reviewed. Clinical, procedural and imaging data was analyzed.

Results: Twenty-two patients with 24 aneurysms treated with the FRED X device, and had completed at least 18 months of follow-up, were included in this study. The rate of complete aneurysm occlusion (Raymond-Roy Class I) was 83.3% at a mean follow-up duration of 21.5 months. One case of major adverse event (4.3%) related to a post-procedural stroke which is also the only case of permanent neurological deficit (4.3%) in our cohort. Three cases of minor adverse events (13.0%) and 2 cases of asymptomatic adverse events (8.7%) were also recorded.

Conclusion: Use of the FRED X FDS to treat intracranial aneurysms has acceptable safety profile and efficacy in the mid-term.

查看原文本刊更多论文

FRED X分流支架治疗颅内动脉瘤：中期血管造影和安全性结果。

目的：本研究的目的是评价FRED X分流支架（FDS）治疗颅内动脉瘤的中期疗效和安全性。FRED X FDS相对较新，关于其长期有效性和安全性的数据有限。方法：回顾性分析2021年3月至2022年7月期间在英国两个中心接受FRED X FDS治疗的颅内动脉瘤患者，随访时间至少为18个月。对临床、手术和影像学资料进行分析。结果：22例24个动脉瘤患者接受了FRED X装置的治疗，并完成了至少18个月的随访。在平均21.5个月的随访期间，完全动脉瘤闭塞率（Raymond-Roy Class I）为83.3%。一例主要不良事件（4.3%）与手术后卒中相关，这也是我们队列中唯一一例永久性神经功能障碍（4.3%）。轻度不良事件3例（13.0%），无症状不良事件2例（8.7%）。结论：使用FRED X FDS治疗颅内动脉瘤具有可接受的中期安全性和有效性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical Neuroradiology CLINICAL NEUROLOGY-RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING

CiteScore

5.00

自引率

3.60%

发文量

106

审稿时长

>12 weeks

期刊介绍： Clinical Neuroradiology provides current information, original contributions, and reviews in the field of neuroradiology. An interdisciplinary approach is accomplished by diagnostic and therapeutic contributions related to associated subjects. The international coverage and relevance of the journal is underlined by its being the official journal of the German, Swiss, and Austrian Societies of Neuroradiology.